Lung neoplasm

This phase 1 trial is testing an experimental therapeutic cancer vaccine called AST-021p in people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if the vaccine is safe and can trigger an immune response against the cancer. Participan…

This phase 2 trial tests whether a vaccine made from immune cell-derived exosomes can slow cancer growth in people with advanced non-small cell lung cancer who have responded to initial chemotherapy. Participants receive low-dose cyclophosphamide followed by weekly injections of …

This study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.

This trial is testing whether giving the immunotherapy drug atezolizumab before surgery can help people with early-stage non-small cell lung cancer. The study includes adults with stage IB to IIIA (non-N2) disease who are eligible for surgery. Participants receive one dose of ate…

This trial tests whether radiofrequency ablation—a procedure that uses heat to destroy cancer cells—can effectively treat lung tumors that cannot be removed with surgery. The study includes people with primary lung cancer or lung metastases, with up to five tumors each no larger …

This study tested a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 61 people with advanced melanoma or other solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could s…

This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …

This early-phase trial tested the drug everolimus (RAD001) alongside radiation therapy in 26 people with advanced non-small cell lung cancer that could not be surgically removed. The goal was to find a safe dose and check for side effects. Participants received everolimus weekly …

This early-phase trial tested whether giving patients their own natural killer (NK) cells, boosted by the drug bortezomib, is safe for treating advanced cancers like leukemia, lung, and pancreatic cancer. Thirty-five adults whose cancers had not responded to standard treatments r…

This phase 2 study tested a combination of three drugs in 46 people with a specific type of lung cancer (EGFR-mutated) that had spread to the lining of the brain and spinal cord (meningeal metastasis). The treatment included a high-dose targeted pill (furmonertinib), an intraveno…

This study tested a new way of giving radiation therapy combined with immunotherapy for people with advanced non-small cell lung cancer that does not have certain genetic mutations. The goal was to see if mixing high-dose and low-dose radiation could help the immune system fight …

This phase II trial is testing whether the immunotherapy drug tislelizumab can help control locally advanced non-small cell lung cancer when given after radiation therapy or sequential chemoradiation. The study enrolls people with stage III lung cancer who cannot tolerate the sta…

This early-phase study tests a new oral drug, furmonertinib, in 30 people with advanced non-small cell lung cancer that has a specific EGFR exon 20 insertion mutation. Some participants have already tried other treatments, while others are newly diagnosed. The goal is to see if t…

This early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to chec…

This phase 2 trial tests whether adding experimental drugs (MK-4830, boserolimab, or lenvatinib) to the standard combination of pembrolizumab and chemotherapy can improve outcomes for people with extensive-stage small cell lung cancer. Participants receive one of these new combin…

This Phase 2 trial tests whether adding chemotherapy (carboplatin and pemetrexed) to the targeted drug osimertinib works better than osimertinib alone for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The study enrolls 80 patients w…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This early-stage trial is testing whether an immunotherapy drug called tislelizumab can be given as a simple injection under the skin instead of through an IV drip for people with advanced non-small cell lung cancer. The study will compare how well the body absorbs the drug in bo…

This early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including non-small cell lung cancer. The drug works by activating immune cells to fight cancer. The main goals were to check safety, find the best dose, and see how the drug move…

This early-phase trial is testing whether adding an experimental drug called alisertib to the standard treatment osimertinib can help people with stage IV EGFR-mutant lung cancer. The study aims to find the safest dose of alisertib when given with osimertinib and to see how the c…

This study tested two new treatments for people with small cell lung cancer that came back after initial chemotherapy. The experimental drugs, lurbinectedin alone or with irinotecan, were compared to standard treatments (topotecan or irinotecan). The goal was to see if the new op…

This phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…

This early-stage trial is testing an investigational therapy called OH2, a modified herpes simplex virus designed to infect and destroy cancer cells while also stimulating the immune system. The study will evaluate OH2 alone or in combination with the immunotherapy drug pembroliz…

This early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…

This trial is testing a new radiation technique called CT-STAR for people with early-stage non-small cell lung cancer located near the center of the chest, where treatment is tricky. The approach uses a machine that takes CT images during each session and adapts the radiation pla…

This trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy can help people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation and have stopped responding to TKI targeted therapy. About 440 participants will be…

This trial is testing whether adding the traditional herbal remedy Bojungikki-tang to the immunotherapy drug pembrolizumab can help people with advanced non-small cell lung cancer. The study includes adults with stage IV disease whose tumors are PD-L1 positive and who have no EGF…

This early-phase trial is testing an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goals are to check safety, how the drug moves through the body, and whether it can shrink tumors. Participants must be able to…

This early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…

This trial tests whether a single dose of risedronate, a bone-strengthening drug, given before stereotactic body radiation therapy (SBRT) for peripheral lung tumors can prevent the rapid bone loss that radiation can cause in nearby ribs. Adults with lung tumors within 2 cm of the…

This study tests whether adding thymosin alpha 1 to standard chemoradiation and immunotherapy helps patients with advanced non-small cell lung cancer complete a full year of immunotherapy. About 114 adults will participate. The goal is to see if this approach improves survival an…

This trial is testing whether adding an experimental drug called HBI-8000 to the immunotherapy nivolumab can safely control advanced melanoma, kidney cancer, and non-small cell lung cancer. The study enrolls adults whose cancers have not responded to prior treatments. Researchers…

This early-phase trial is testing an experimental drug called SPYK04 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for early signs that SPYK…

This study tested a new drug combination for people with a specific type of advanced lung cancer (EGFR-mutant non-small cell) that had stopped responding to standard targeted pills. The trial enrolled 95 adults and gave them two different combinations of immunotherapy (atezolizum…

This phase 2 trial tests whether adding lenvatinib to a standard chemotherapy-plus-immunotherapy regimen can shrink tumors in people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation. Participants will receive lenvatinib capsules daily along …

This phase 1 trial is testing an experimental drug called STP707 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see whether the drug can slow or shrink tumors. Participants receive STP707 b…

This trial tests an experimental drug, RSO-021, given directly into the chest cavity of people with malignant pleural effusion—a buildup of fluid around the lungs caused by advanced solid tumors or mesothelioma. The study aims to find a safe dose and check for early signs that th…

This completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…

This phase 3 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with stage II-III non-small cell lung cancer. Participants receive either toripalimab plus chemotherapy or a placebo plus chemotherap…

This early-phase trial is testing an experimental drug called SM3321 in people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose. Participants receive SM3321 as a we…

This phase II trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy and radiation can help people with stage III non-small cell lung cancer that cannot be surgically removed. About 50 participants will receive the combination treatment, and …

This study tested whether adding a bronchoscopy-guided treatment to standard immunotherapy and chemotherapy could help people with advanced central non-small cell lung cancer. The trial included 33 adults whose cancer could not be surgically removed. The goal was to see if the tr…

This trial investigates an experimental oral drug, LY3143921 hydrate, which blocks a protein called Cdc7 that cancer cells need to divide. It is being tested in adults with advanced solid tumours, including colorectal, ovarian, lung, and pancreatic cancers, that have not responde…

This early-stage trial tests an experimental drug called JS015 in people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the best dose, and see how the body processes it. Up to 12 participants will recei…

This trial investigates whether combining stereotactic body radiotherapy (SBRT), a precise form of radiation, with the immunotherapy drug nivolumab is safe and tolerable for people with early-stage non-small cell lung cancer. Participants receive SBRT followed by nivolumab infusi…

This trial tests an experimental drug called enfortumab vedotin, which is designed to seek out and destroy cancer cells that have a specific protein called Nectin-4 on their surface. The study includes people with metastatic urothelial cancer (a type of bladder cancer) and other …

This early-stage trial tests an experimental drug called SHR-7367 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 22 participants will …

This study looks at whether giving targeted drugs called ROS1 inhibitors before surgery can help people with a rare form of lung cancer. The drugs, entrectinib or crizotinib, are designed to attack cancer cells with a specific genetic change. Researchers will check how much the t…

This early-phase trial tests an experimental oral drug, MK-6598, both by itself and in combination with the immunotherapy pembrolizumab (Keytruda) in adults with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see early signs of t…

This study tests whether a new drug called RPH-075, a biosimilar of pembrolizumab (Keytruda), works as well as the original in people with skin melanoma, lung cancer, or head and neck cancer. Participants receive a single dose of either RPH-075 or Keytruda, and researchers compar…

This phase 2 trial tests the experimental drug LDK378 in adults with advanced non-small cell lung cancer that has a specific genetic change called a ROS1 rearrangement. Participants must have already received at least one platinum-based chemotherapy and their cancer must have pro…

This study reviews medical records of 35 adults with a specific lung cancer (ROS1-positive NSCLC) that had not been controlled by other treatments. All participants took lorlatinib pills at home until their cancer stopped responding. Researchers will analyze how long the drug kep…

This early-phase study tests an experimental drug called ANV600, given alone or with the immunotherapy Keytruda, in 240 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink tumors. Beca…

This study tested whether avoiding the hippocampus during whole-brain radiation could reduce memory side effects in people with small cell lung cancer. Over 400 patients received either standard whole-brain radiation or a version that spares the hippocampus. The goal was to see i…

This study tests a new drug called pegilodecakin, a lab-made version of a natural immune protein (interleukin-10), in people with advanced solid tumors such as melanoma, lung, breast, prostate, ovarian, kidney, colorectal, and pancreatic cancers. The drug is given as a daily shot…

This trial investigates whether adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy (carboplatin and etoposide) helps people with a rare and aggressive lung cancer called large cell neuroendocrine carcinoma (LCNEC). The study enrolls adults with advanc…

This phase II trial tests whether adding canakinumab, an anti-inflammatory drug, to standard chemoradiation and immunotherapy (durvalumab) helps control locally advanced non-small cell lung cancer. About 41 participants will receive the combination to see if it improves progressi…

This study tested whether adding a personalized dendritic cell vaccine to the immunotherapy drug atezolizumab could help people with extensive-stage small cell lung cancer stay stable longer after initial chemotherapy. Twenty participants received standard chemo plus atezolizumab…

This study investigates whether 4DCT scans—which capture how a tumor moves when a person breathes—can be used to design radiation plans that avoid high-functioning healthy lung tissue. People with non-small cell lung cancer who are scheduled for radiation therapy may join. The go…

This study tests a device called the LungVision system, which uses artificial intelligence to help surgeons locate small lung nodules during minimally invasive surgery. The system combines CT scans with live X-ray images to guide a tool to the nodule, then injects a dye to mark i…

This study tests whether combining two targeted drugs, avutometinib and adagrasib, can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants must have already tried a KRAS G12C inhibitor and seen their c…

This early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…

This early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…

This trial tests whether a gentler suction level (-2 cmH2O) on chest tubes after keyhole lung cancer surgery works as well as the standard stronger suction (-10 cmH2O). The goal is to see which setting allows tubes to be removed sooner and causes fewer complications. About 230 ad…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This phase II trial tests whether a low-dose, frequent schedule of the chemotherapy drug vinorelbine, taken orally, can boost the effects of the immunotherapy atezolizumab in people with stage IV non-small cell lung cancer. The study enrolls adults whose cancer has progressed aft…

This Phase 3 trial tested a new targeted therapy, lazertinib, against the standard drug gefitinib in 393 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if lazertinib could keep cancer from growing longer. Participants took either lazertinib or g…

This phase 3 trial tests whether adding vibostolimab to pembrolizumab (Keytruda) helps people with PD-L1 positive metastatic non-small cell lung cancer live longer than pembrolizumab alone. Over 1,200 participants received either the combination or pembrolizumab every three weeks…

This study tested whether adding another drug to the immunotherapy pembrolizumab (Keytruda) can help people with advanced non-small cell lung cancer whose disease got worse after initial treatment. 128 participants received one of three drug combinations. The goal was to see if t…

This early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…

This phase 2 study tested a combination of two drugs—ivonescimab (AK112) and irinotecan liposome—in 60 people with extensive-stage small-cell lung cancer whose disease had worsened after standard first-line therapy. The goal was to see if the combo could slow cancer growth and sh…

This large phase III trial tested whether adding bevacizumab (Avastin) to standard chemotherapy after complete lung cancer surgery could help patients live longer. Over 1,500 patients with stage IB to IIIA non-small cell lung cancer took part. The study found that adding bevacizu…

This phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…

This phase II trial studied 168 people with extensive-stage small cell lung cancer. Researchers added either vismodegib or cixutumumab to standard chemotherapy (cisplatin and etoposide) to see if these combinations worked better than chemo alone. The goal was to slow cancer growt…

This study tested whether adding veliparib (a PARP inhibitor) to standard chemotherapy (cisplatin and etoposide) helps people with extensive stage small cell lung cancer or certain other lung cancers that have spread. In the first phase, researchers found the best dose of velipar…

This phase 2 trial tests the drug crizotinib (XALKORI) in people with advanced non-small cell lung cancer that has spread and carries a change in the ROS1 or MET gene. Participants take crizotinib by mouth twice daily. The study aims to see how well the drug shrinks tumors and de…

This phase III trial investigates whether sunitinib, a drug that blocks tumor blood vessel growth, can help patients with advanced non-small cell lung cancer maintain their response after initial chemotherapy. Participants who did not worsen after four cycles of platinum-based ch…

This phase 3 trial tested the immunotherapy drug cemiplimab against standard platinum-based chemotherapy in 712 patients with advanced or metastatic non-small cell lung cancer that has high PD-L1 levels. The study aimed to see if cemiplimab improves overall survival and delays ca…

This large phase 3 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help people with a specific type of advanced lung cancer live longer than standard chemotherapy. Over 1,200 participants with PD-L1 positive non-small cell lung cancer were randomly assi…

This Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…

This pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …

This phase 2 study tested three different drug combinations in 151 people with advanced non-small cell lung cancer that had not been treated before. The drugs help the immune system attack cancer cells. Researchers measured how many patients' tumors shrank or stopped growing, and…

This study looked at adding sunitinib malate (a drug that blocks tumor blood flow) to standard chemotherapy for people with extensive-stage small cell lung cancer. The trial involved 156 participants and aimed to find the best dose and see if maintenance sunitinib after chemo cou…

This early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…

This study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…

This phase II trial tested a new drug called AK104 (a bispecific antibody that targets two immune checkpoints) combined with the chemotherapy docetaxel in 44 adults with advanced non-small cell lung cancer whose disease had progressed after platinum-based chemotherapy and an anti…

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This study tested the safety and effectiveness of Vizimpro (dacomitinib) in 40 Japanese patients with EGFR-mutated non-small cell lung cancer that could not be surgically removed or had returned. Researchers tracked side effects, especially interstitial lung disease, and measured…

This study tested giving immunotherapy drugs (nivolumab alone or with relatlimab) for four weeks before surgery in 90 people with early-stage non-small cell lung cancer. The goal was to see if this approach is feasible and helps shrink tumors before removal. Results help determin…

This study tested whether matching drug combinations to specific biomarkers in advanced non-small cell lung cancer could improve response. 245 patients who had not received prior treatment were grouped by two biomarkers (GEP and TMB) and given pembrolizumab plus another drug. The…

This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. Th…

This early-phase study tested a combination of two drugs, bexarotene and Iressa, in 6 people with advanced non-small cell lung cancer who had already tried standard treatments. The goal was to see if the combination was safe and could help control the disease. The study looked at…

This study tested an oral drug called PLB1001 in 145 people with advanced non-small cell lung cancer whose tumors have a specific genetic change (c-Met dysregulation). The main goal was to see how many patients' tumors shrank or disappeared. The drug is taken twice daily and aims…

This completed Phase 4 trial tested two different doses of chemotherapy (standard and low-dose) combined with the immunotherapy drug Sintilimab in 20 people with advanced squamous non-small cell lung cancer. The goal was to see if the lower-dose combination could shrink tumors an…

This study looked at whether giving immunochemotherapy in the morning or afternoon affects how long people with advanced non-small cell lung cancer live without their disease getting worse. 210 patients were randomly assigned to receive treatment before or after 3 PM. The goal is…

This early-stage trial tested a new drug called PF-07257876 in 29 people with advanced lung, head/neck, or ovarian cancers that had stopped responding to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals wer…

This completed study looked at how patients with advanced EGFR-positive non-small cell lung cancer fared while taking dacomitinib in real-world settings in Taiwan. Researchers tracked 29 adults who took dacomitinib pills at home until their cancer stopped responding. The goal was…

This study tested whether a shorter course of radiation (hypofractionated) given with chemotherapy works as well as the standard longer radiation course for people with limited-stage small cell lung cancer. 860 adults aged 18-70 with early-stage disease took part. The main goal w…

This phase 3 study tested alectinib against crizotinib in 303 people with advanced ALK-positive non-small cell lung cancer who had not received prior treatment. Participants took one of the two drugs twice daily until their cancer worsened or side effects became too severe. The m…

This phase 2 study tested a combination of two drugs—KN046 (an immunotherapy) and axitinib (a targeted therapy)—in 95 people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combo could shrink tumors and how safe it was. The tr…

This study tested a combination of two drugs, tislelizumab and anlotinib, in 29 people with advanced pulmonary pleomorphic carcinoma, a rare and aggressive lung cancer. The goal was to see if the combo could shrink tumors or slow the disease. Participants had stage III or IV canc…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…

This study tested whether combining two targeted drugs, savolitinib and osimertinib, works better than standard chemotherapy for people with advanced non-small cell lung cancer that has a specific genetic change (MET amplification) and has stopped responding to initial treatment.…

This study tested whether adding an experimental drug (CCR2/5-inhibitor or anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 participants receive…

This phase 3 trial tested whether adding plinabulin to the chemotherapy drug docetaxel helps people with advanced non-small cell lung cancer live longer. 559 participants who had already tried one or two prior treatments received either the combination or docetaxel alone. The stu…

This study tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy and radiation helps people with advanced lung cancer whose disease has spread to the brain. The trial included 60 patients who had not received chemotherapy before. Researchers measured …

This phase 3 study tested whether adding the immunotherapy drug cemiplimab to standard chemotherapy helps people with advanced non-small cell lung cancer live longer. The trial enrolled 789 participants and compared different drug combinations. The main goal was to see if the com…

This phase 2 study tested whether adding the targeted drug erlotinib to standard chemotherapy (docetaxel) works better than chemotherapy alone for people with advanced non-small cell lung cancer whose first treatment stopped working. 156 participants were randomly assigned to one…

This study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…

This study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…

This early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …

This study tested a new drug (ningetinib) combined with an existing targeted therapy (gefitinib) in 108 people with advanced lung cancer whose cancer had stopped responding to previous treatments. The goal was to find the safest dose and see if the combination could shrink tumors…

This early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…

This phase 3 study tested whether adding the immunotherapy drug sintilimab to standard chemotherapy helps people with advanced non-squamous non-small cell lung cancer. 397 participants received either sintilimab plus chemo or a placebo plus chemo. The main goal was to see if the …

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This phase 2 trial tested a combination of chemotherapy (carboplatin or cisplatin plus pemetrexed) and immunotherapy (atezolizumab, with or without bevacizumab) in 150 people with advanced non-squamous non-small cell lung cancer that has EGFR, ALK, or ROS1 mutations and has progr…

This early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …

This phase 2 trial tested a drug called patritumab deruxtecan (HER3-DXd) in 63 patients with breast cancer, lung cancer, or other solid tumors that had spread to the brain or the lining of the brain and spinal cord. The drug is designed to seek out and destroy cancer cells carryi…

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

This study tested a new way to deliver high-dose radiation to small lung tumors in just one day, instead of the usual two to three weeks. Ten patients with early-stage lung cancer or limited lung metastases received a single session of stereotactic body radiotherapy (SBRT) using …

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…

This phase 2 trial tested a combination of FLT3 ligand immunotherapy (CDX-301) and stereotactic body radiotherapy (SBRT) in 33 adults with advanced non-small cell lung cancer that had worsened after standard treatments. The goal was to see if this approach could slow cancer growt…

This study tested whether customizing chemotherapy based on specific gene mutations (EGFR and BRCA1) could improve outcomes for 153 patients with advanced lung adenocarcinoma. Participants received treatments matched to their tumor's genetic profile. The goal was to see if this p…

This trial tested several targeted drugs in people with non-small cell lung cancer whose tumors had specific genetic changes. The goal was to see if these drugs could shrink tumors or delay cancer growth. Over 400 participants received treatment based on their tumor's genetic pro…

This early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…

This study tested whether adding a precise, high-dose radiation treatment called CyberKnife after standard chemo and radiation could help people with stage III non-small cell lung cancer. It included 35 patients who had 1 to 3 small tumors left after initial treatment. The goal w…

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…

This phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…

This phase 2 study tested a combination of four drugs—atezolizumab, bevacizumab, a platinum drug, and pemetrexed—in 22 people with advanced EGFR-mutant non-small cell lung cancer whose disease had progressed after EGFR-targeted therapy. The goal was to see how many patients' tumo…

This early-phase study tested whether combining the immunotherapy drug pembrolizumab with standard palliative radiation is safe for people with advanced lung cancer. Twenty-four participants received different doses of pembrolizumab alongside radiation, then continued pembrolizum…

This study tested a combination of two immunotherapy drugs (eftilagimod alpha and pembrolizumab) in 187 people with advanced lung cancer or head/neck cancer that had not been treated or had stopped responding to prior therapy. The goal was to see if the combination could shrink t…

This study tested whether using PET/CT scans during treatment to adjust radiation plans can improve outcomes for people with stage III non-small cell lung cancer. 138 participants were randomly assigned to receive either standard radiation or radiation guided by mid-treatment sca…

This phase 2 trial tested a combination of two drugs, tucidinostat and tislelizumab, as a first treatment for people with a type of advanced lung cancer that has a specific marker (PD-L1 positive). The study involved 118 participants and aimed to see if the combo could delay canc…

This study tested a new drug called AZD9291 in 603 people with advanced non-small cell lung cancer whose tumors had started growing again after previous targeted therapy. The main goals were to find the safest and most effective dose, measure how the drug moves through the body, …

This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…

This early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…

This Phase 3 trial tested whether adding custirsen to the chemotherapy drug docetaxel helps people with advanced non-small cell lung cancer live longer. The study involved 664 patients who had already tried one platinum-based treatment. Researchers compared survival between those…

This study tested whether giving the drug durvalumab after precise radiation therapy (SBRT) helps people with early-stage lung cancer stay cancer-free longer. About 106 patients with stage I non-small cell lung cancer who could not have surgery or chose not to were randomly assig…

This early-phase trial tested two experimental drug combinations in 37 people with advanced EGFR-mutant lung cancer that no longer responded to the targeted therapy osimertinib. The goal was to find safe, tolerable doses of alisertib or sapanisertib when given together with osime…

This early-phase trial tested the drug cilengitide given continuously along with standard chemotherapy and radiation in 14 patients with locally advanced non-small cell lung cancer. The main goal was to find the highest safe dose of cilengitide when used this way. Researchers als…

This phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…

This study tested a program called CEASE that helps lung cancer patients quit smoking. The program was built into regular doctor visits and included screening, counseling, and referrals. Researchers studied 263 patients to see if the program improved quit rates and how well it wo…

This study tracked 296 patients with advanced or recurrent non-small cell lung cancer who received a combination of IMJUDO, IMFINZI, and platinum-based chemotherapy. The goal was to see how safe the treatment is in everyday medical practice. Researchers recorded any side effects …

This study tested whether tracking daily steps with a simple pedometer could help identify cancer patients at high risk of being hospitalized during chemoradiotherapy. 40 adults with head and neck, lung, esophageal, or stomach cancer wore a pedometer and received extra support li…

This phase 2 trial tested a new cancer vaccine (IO102-IO103) combined with the immunotherapy drug pembrolizumab as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. The study enrolled 63 participants to see if the combination is safe a…

This study tested a combination of two drugs (durvalumab and anlotinib) plus standard chemotherapy as a first treatment for people with extensive-stage small-cell lung cancer, a fast-growing cancer. 34 adults took part. The goal was to see if the combo helps delay cancer growth o…

This early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …

This phase 2 trial tested a combination of the immunotherapy drug pembrolizumab and a personalized 4-week course of radiotherapy in 25 patients with advanced non-small cell lung cancer whose tumors had high PD-L1 levels. The goal was to see if this approach could control the canc…

This study tested the drug durvalumab in 446 people with advanced non-small cell lung cancer who had already tried at least two prior treatments. The goal was to see if the drug could shrink tumors or slow the disease. Participants received infusions every two weeks for up to 12 …

This study tested giving immunotherapy drugs (nivolumab alone or with ipilimumab) or immunotherapy plus chemotherapy before surgery for people with early-stage non-small cell lung cancer (stages I to IIIA). The goal was to see if these treatments could shrink or eliminate the tum…

This study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deli…

This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…

This phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…

This study tested a combination of an immune-boosting drug (durvalumab) and a precise, high-dose radiation treatment (SBRT) for people with stage III lung cancer that hadn't spread. The goal was to see if adding SBRT after standard chemoradiation could help control the cancer lon…

This early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …

This early-phase trial tested an experimental drug called BAT8010 in 23 people with advanced or metastatic solid tumors who had no other standard treatment options. The main goals were to check safety, find the best dose, and see if the drug shows any sign of shrinking tumors. Pa…

This study tested an oral targeted drug called capmatinib in 36 Chinese adults with advanced non-small cell lung cancer that has a specific MET gene mutation (exon 14 skipping). The drug aims to block faulty signals that help cancer grow. Researchers measured how many patients' t…

This early-phase study tested a personalized immunotherapy (iNeo-Vac-P01) in 6 patients with stage III colorectal or non-small cell lung cancer who had already completed surgery and standard adjuvant therapy. The vaccine was designed to target unique neoantigens from each patient…

This early-phase trial tested a light-measuring system used during photodynamic therapy (PDT) for people with malignant mesothelioma, non-small cell lung cancer, or other pleural cancers. Nine participants received the drug porfimer sodium, which becomes active when exposed to li…

This study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…

This phase 3 trial tested a portable device that creates electric fields to disrupt cancer cell division in 291 people with stage 4 non-small cell lung cancer that had worsened after initial chemotherapy. Participants wore the device on their chest while continuing standard treat…

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…

This study tested the immunotherapy drug pembrolizumab in 35 people with early-stage non-small cell lung cancer. Participants received the drug before and after surgery to see if it could help the immune system attack cancer cells. The main goal was to check if surgery could stil…

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…

This study tested whether a short course of radiation to one tumor site could help immunotherapy drugs work better in people with advanced lung or head/neck cancers. 76 participants received radiation within two weeks of starting their immunotherapy. The main goal was to see if t…

This study looked at whether adding a structured addiction treatment program to standard cancer care helps patients with head and neck or lung cancer quit smoking and reduce alcohol use. 133 patients were randomly assigned to either the integrated program or usual care. The main …

This early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if the combination is safe and tolerable. Participants had stage IIIB, IIIC, IV…

This early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…

This Phase 3 study tested whether adding bevacizumab (Avastin) to erlotinib (Tarceva) works better than erlotinib alone for Chinese patients with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations. Over 300 patients were randomly assigned to one of the t…

This study tested a drug called daratumumab in 8 people with a specific genetic mutation (STK11/LKB1) in advanced non-small cell lung cancer who had already tried other treatments. The goal was to see if the drug could shrink tumors. The study was small and designed to find early…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This study looked at how well the drug lorlatinib works for people with advanced non-small cell lung cancer that has a specific gene change (ALK). All 73 participants had already tried other treatments and took lorlatinib pills at home. The study tracked how long the drug kept th…

This early study tested combining the immunotherapy drug pembrolizumab with precise radiation (stereotactic radiosurgery) in 25 people with melanoma or lung cancer that had spread to the brain. The main goal was to check for serious side effects. Researchers also tracked how long…

This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This trial tested a new drug called AK112 in 108 people with advanced non-small cell lung cancer. The drug targets both PD-1 and VEGF to attack cancer cells and cut off their blood supply. The study aimed to see if the drug shrinks tumors and how safe it is. Participants had stag…

This early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…

This study tested a combination of two drugs, SHR-1210 (given through a vein) and Apatinib (a daily pill), in 210 adults with advanced non-small cell lung cancer that had stopped responding to standard chemotherapy. The goal was to see if the combo could shrink tumors and to chec…

This study followed 272 adults with extensive-stage small cell lung cancer who were taking the drug Zepzelca. Researchers wanted to see how well the drug worked and how safe it was in real-world settings, not just in controlled trials. The goal was to measure tumor shrinkage, sur…

This study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…

This study compared four different smoking cessation programs to see which one works best for underserved smokers who are getting lung cancer screening. Over 3,200 participants from four U.S. health systems took part. The goal was to help them quit smoking for at least six months…

This study tested a combination of two drugs—bevacizumab and a higher dose of icotinib—in 35 people with advanced non-squamous lung cancer that has a specific genetic change (EGFR L858R). The goal was to see if this combo could delay cancer growth better than standard treatment. …

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…

This early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …

This study tested a combination of two drugs—nivolumab (Opdivo) and ALT-803—in 67 people with advanced non-small cell lung cancer that had not responded to prior treatments. The goal was to find a safe dose and see if the combination could shrink tumors. The trial is now complete…

This phase 3 trial tested whether adding lenvatinib to pembrolizumab helps people with untreated advanced non-small cell lung cancer whose tumors have PD-L1 levels of 1% or higher. Over 600 participants received either the combination or pembrolizumab alone. The study measured ho…

This study looked at 45 patients with limited-stage small-cell lung cancer who received the immunotherapy drug durvalumab after standard chemoradiation. The goal was to see how long patients went without their cancer getting worse. Because this was a small, single-center review, …

This early-phase trial tested two oral drugs, palbociclib and binimetinib, in 34 people with advanced lung cancer that has a specific change in the KRAS gene. The goal was to find the safest dose and see if the combination can slow cancer growth. The study is complete, but result…

This study tested giving the immunotherapy drug tislelizumab, alone or with other drugs, before surgery for people with stage II to IIIA non-small cell lung cancer that could be removed. The goal was to see if this approach could shrink tumors and improve outcomes. 121 adults too…

This study tested whether adding bevacizumab to osimertinib helps people with advanced non-small cell lung cancer that has a specific genetic change (EGFR and T790M mutations). 155 adults who had already tried other treatments took part. The main goal was to see if the combinatio…

This early-phase trial tested whether injecting the chemotherapy drug cisplatin directly into lung tumors (during a bronchoscopy) is safe for people with early-stage, resectable non-small cell lung cancer. Only 6 participants were enrolled, and the main goal was to find the highe…

This study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…

This early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…

This study followed 22 cancer patients who were already taking bintrafusp alfa in earlier trials, to see how safe it is over the long term and how long they live. Participants continued receiving the drug until it was no longer helping or became available commercially. The main g…

This study tested whether a procedure called local ablative therapy (LAT) can help control metastatic non-small cell lung cancer (NSCLC) when a blood test shows signs of remaining cancer (minimal residual disease, or MRD). 37 patients with stage IV NSCLC received LAT to all visib…

This study tested whether adding aspirin to the targeted drug osimertinib helps control advanced EGFR-positive non-small cell lung cancer. 216 participants received the combination as their first treatment. The goal was to see if it delays cancer progression and improves survival…

This early-phase study tests two experimental drugs, BI 765049 and ezabenlimab, in adults with advanced solid tumors like colorectal, lung, and pancreatic cancer. The main goal is to find the highest safe dose of BI 765049 alone and in combination with ezabenlimab. Participants r…

This study looked at whether a special care plan led by a geriatrician and a nurse could improve survival and quality of life for older adults (70+) with advanced cancer. 792 patients with breast, colorectal, lung, prostate, bladder, ovarian cancer, or lymphoma took part. The app…

This early-phase trial tested adding the anti-parasitic drug atovaquone to standard chemotherapy and radiation for people with locally advanced non-small cell lung cancer. The main goal was to find the safest dose of atovaquone in this combination. Twenty-one participants receive…

This early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…

This early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…

This early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…

This early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…

This study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…

This study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This study tested whether adding a new drug (LY2875358) to the standard treatment erlotinib helps people with advanced non-small cell lung cancer that has a specific gene mutation. All 168 participants first took erlotinib alone for 8 weeks. Those whose cancer did not worsen were…

This study tested a combination of two drugs—pembrolizumab (Keytruda) and Imprime PGG—in 35 people with advanced non-small cell lung cancer whose disease had worsened after initial treatment. The goal was to find a safe dose and see if the combination could slow cancer growth. Th…

This pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare …

This early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells tha…

This early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…

This study tested a new surgical stapler (easyEndo™ Lite) in 30 people undergoing lung cancer surgery. The goal was to see if the device safely cuts and seals lung tissue. Researchers checked for successful sealing, surgery time, blood loss, and complications. The study is comple…

This study tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) after standard chemoradiation could better control stage III lung cancer compared to nivolumab alone. 105 patients were randomly assigned to one of the two treatment groups. The main goal was to s…

This study investigates whether a liquid biopsy taken from the airways during a bronchoscopy can help diagnose lung cancer and identify genetic mutations. The approach aims to be less invasive and faster than traditional tissue biopsies. Researchers will compare the accuracy of t…

This study tests a new, ultra-sensitive blood test (NGS) to detect EGFR gene mutations in patients with advanced lung cancer. Researchers will compare it to the current standard test using stored blood samples from 130 patients. The goal is to see if the new method finds more mut…

This study is testing a new breath test called OWL-EVO1 to see if it can accurately tell the difference between people who have lung cancer and those who do not. The test involves breathing into a device after taking a special probe. Researchers are enrolling adults aged 45-85 wh…

This early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…

This completed Phase 1 study tested a new radioactive imaging agent called [123I]I-DARPIN-Ec1 in 10 people with lung or ovarian cancer. The goal was to see how the agent spreads in the body and whether it can help spot tumors on SPECT scans. Researchers compared the new scan resu…

This study tests a special SPECT imaging agent that seeks out a protein called LRRC15, found on many aggressive cancers like pancreatic, breast, lung, and brain tumors. The goal is to see if this scan can help doctors diagnose and stage these cancers more accurately. Healthy volu…

This study tested whether an ultra-low dose CT scan, combined with a deep-learning AI reconstruction, can detect lung nodules as accurately as the standard low-dose CT. 70 adults having a chest CT for nodule check-up or follow-up received an extra ultra-low dose scan. The goal wa…

This study investigates whether a machine that analyzes exhaled breath can identify a unique chemical signature for lung cancer. Researchers will compare breath samples from people with lung cancer (before and after surgery) and healthy controls. The goal is to develop a non-inva…

This study aimed to create easy, non-invasive tests using blood and saliva to find markers of certain cancers, like breast and lung cancer. Researchers worked with 250 adults who had these cancers but hadn't started treatment yet. The goal was to improve early detection and monit…

This study tested a new imaging tool called needle-based confocal laser endomicroscopy (nCLE) to help doctors locate lung nodules during robotic-assisted bronchoscopy. 53 adults with lung nodules at risk for cancer took part. The goal was to see if the tool could safely and accur…

This study tested whether specially trained dogs can identify breast, lung, prostate, or colorectal cancer by sniffing breath samples collected on masks. Over 1,300 people provided breath samples before their regular cancer screening or biopsy. The dogs' results were compared to …

This study tested a new type of PET scan (68Ga-FAPI) to see if it can find lung cancer and its spread more accurately than the standard FDG-PET scan. 58 adults with known or suspected lung cancer received both scans, and results were compared to tissue samples or follow-up. The g…

This study tested a special fluorescent dye called VGT-309 that makes lung cancer cells glow during surgery. About 89 people with known or suspected lung cancer received the dye before their operation. The goal was to see if the dye helps surgeons find tumors that are hard to see…

This study tested whether a simple breath test can predict if cancer patients will respond to immunotherapy drugs. Researchers used an electronic nose device to analyze breath samples from 190 patients with lung, melanoma, kidney, bladder, or head and neck cancers. The goal is to…

This study tested a new smart probe that uses electrical signals to tell the difference between healthy lung tissue and tumors during a biopsy. 30 adults with lung lesions took part. The goal was to see if the probe could help doctors make more accurate diagnoses during the proce…

This pilot study tested whether low-dose CT scans can help find lung cancer early in HIV-positive people who are heavy smokers. Researchers scanned 450 participants to see how many had lung cancer and what types were found. The goal was to learn if this screening method is useful…

This study tested whether a special PET scan (called 18F-DOPA PET-CT) can find brain metastases as well as or better than standard MRI in people with lung cancer, breast cancer, or melanoma. 32 adults with untreated brain metastases took part. The goal was to see if this PET meth…

This completed study tested a tool called MyLungHealth, delivered through a patient portal, to help more people get screened for lung cancer. Over 31,000 participants aged 50-79 with a smoking history were involved. The tool aimed to identify who was eligible for screening and en…

This study tested whether a blood test can detect ALK gene rearrangements in lung cancer patients, which currently requires an invasive tumor biopsy. Researchers analyzed circulating tumor cells from blood samples of 206 patients with advanced lung cancer. The goal was to see if …

This study looked at whether a blood test for circulating tumor cells (CTCs) can help detect lung cancer earlier in people at very high risk: smokers and ex-smokers with COPD. Researchers combined this blood test with low-dose CT scans over three yearly screenings in 683 particip…

This study looked at whether a blood test can find gene changes in people with advanced lung cancer. 22 adults gave a blood sample, and the results were compared to standard tissue tests. The goal was to see if the blood test is a reliable and practical option for guiding treatme…

This study looked at whether a simple blood test (liquid biopsy) can detect EGFR gene mutations in people with advanced non-small cell lung cancer. Researchers collected blood samples from 581 patients and compared the results with standard tissue testing. The goal was to see if …

This study tested whether a new type of PET scan, which looks for a protein called PD-L1 on cancer cells, can predict how well patients with advanced lung cancer will respond to the immunotherapy drug nivolumab. Eighty patients received the scan before starting treatment. Researc…

This pilot study tests a peer-led program designed to help Black Veterans at high risk for lung cancer get screened. Veterans who have not yet had lung cancer screening will receive group orientations and one-on-one support from a peer to navigate the process. The study aims to s…

This study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…

This study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…

This early-phase study tested a vaccine called CIMAvax-EGF in 20 people at high risk for lung cancer or survivors at risk of recurrence. The vaccine works by helping the body make antibodies against a protein that can fuel cancer growth. Researchers checked for side effects and m…

This phase 2 trial tests whether inhaling a blend of peppermint and lemon essential oils can reduce nausea and vomiting in people receiving their first chemotherapy for a solid tumor. Participants will inhale the oils four times daily and whenever nausea strikes, with symptoms tr…

This study tested a structured physiotherapy program for 60 people who had lung cancer surgery. The program included breathing exercises, early walking, and posture training during their hospital stay. Researchers measured how long people stayed in the hospital and checked vital …

This pilot study tests whether a daily herbal supplement made from Lindera obtusiloba can improve quality of life for people with non-small cell lung cancer who are receiving PD-1 or PD-L1 inhibitor immunotherapy. About 20 adults will take the supplement for 8 weeks alongside the…

This trial tests whether a new care approach, called PediQUEST Response, can improve quality of life for children, adolescents, and young adults with advanced cancer. Participants use an app to regularly report symptoms and quality of life, and a palliative care team receives the…

This study tests whether teaching family caregivers about lung cancer care—through a handbook and personalized guidance—can reduce stress and improve quality of life for patients undergoing lung cancer surgery. The trial involves 160 patients and their caregivers, with some recei…

This study tests a psychosocial program called Conquer Fear Support (CFS) for people with stage III or IV lung or gynecologic cancer who are experiencing fear of cancer progression. The program includes psychoeducation, attention training, worry management, and detached mindfulne…

This study tests whether using a virtual reality headset during PICC line placement can reduce anxiety and pain in cancer patients. About 120 adults will be randomly assigned to either receive VR plus standard care or standard care alone. The goal is to see if this non-drug appro…

This trial tests whether adding nebulized ketamine to lidocaine before a fiberoptic bronchoscopy reduces coughing and discomfort compared to lidocaine alone or standard spray. About 134 adults scheduled for bronchoscopy will receive one of three premedication approaches. The stud…

This study looks at two ways of delivering palliative care—specialized support to ease symptoms and stress—for people recently diagnosed with advanced lung cancer. One approach starts with basic palliative care and adds more if needed, while the other provides full palliative car…

This study tested whether monthly 45-minute psychological interviews over 6 months could reduce post-traumatic stress symptoms in cancer patients affected by the COVID-19 pandemic. It included 29 adults with solid tumors who had moderate to high PTSD symptoms. The goal was to see…

This trial tests whether immersive virtual reality or relaxing nature videos can reduce symptom severity, distress, and improve quality of life in people with lung cancer who are starting chemotherapy. Participants will be randomly assigned to one of three groups: virtual reality…

This trial tests whether a wearable sensor called the Alio Smart Patch can help catch early signs of febrile neutropenia, a serious infection risk from chemotherapy. Thirty adults with certain cancers will wear the patch and a glucose monitor at home, with a remote care team watc…

This study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…

This study investigates whether a 12-week program of tai chi and qigong (called Body Mind Training) can reduce fatigue in male cancer survivors aged 55 and older. Participants are randomly assigned to the mind-body training, a light exercise-only group, or a usual-care group. Res…

This trial tests whether daily bright light therapy can improve sleep and reduce biological aging in people with lung cancer. Participants wear a light visor for 4 weeks and track sleep, fatigue, and stress. The study compares bright light to usual light exposure to see if it hel…

This trial investigates whether an 8-week systematic symptom management nursing program can improve quality of life, self-management skills, and psychological resilience in people with advanced (stage IIIB–IV) lung cancer. Participants are randomly assigned to receive either rout…

This pilot study tests a breathing method called percussive ventilation breathhold (PVB) to help people hold still during lung cancer radiation. The goal is to see if the technique can be used successfully by healthy volunteers and lung cancer patients. If it works, it may allow …

This pilot study tested whether a smartphone-based program could help high-risk patients recover their breathing after lung surgery. Fifty-eight adults who had lung resection and were either older or had reduced lung function were split into two groups: one used a smartphone app …

This study tested whether a 4-week home exercise program, guided by a wearable fitness device and supervised remotely, could help lung cancer patients get in better shape before surgery. Thirty people with early-stage non-small cell lung cancer participated. The goal was to see i…

This study tested whether spraying a drug called terlipressin into the airways before taking biopsy samples can reduce bleeding. The goal was to allow doctors to safely take more tissue samples, which could improve the chances of diagnosing lung cancer. The trial involved 130 adu…

This study tested whether a personalized exercise program helps people with early-stage lung cancer or cancer that spread to the lungs recover better after surgery. 182 participants were randomly assigned to either the exercise program or usual care. The main goal was to see if t…

This study tested whether personalized motivational messages sent via apps like WhatsApp could improve thinking skills and physical activity in lung cancer survivors who have memory or concentration problems. 124 survivors wore activity trackers and received custom messages for t…

This study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…

This study tested an investigational drug called ponsegromab in 187 adults with lung, pancreatic, or colorectal cancer who also had cachexia—a condition causing severe weight loss, loss of appetite, and fatigue. The goal was to see if ponsegromab could help patients gain weight a…

This study tested two ways to manage pain in 70 children undergoing chest surgery. One method, the erector spinae plane block, was compared to the standard epidural block. The goal was to see which provides better pain relief and keeps the heart rate and blood pressure more stabl…

This study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…

This early-phase trial tested a treatment called photodynamic therapy for people with advanced lung cancer that blocks airways. Patients received a light-sensitive drug followed by a laser to activate it inside the tumor. The goal was to see if the treatment is safe and can shrin…

This study tested whether a mobile app with videos and written guides, given before chest surgery, helps patients recover better. 128 adults scheduled for elective chest surgery were split into two groups: one used the app, the other got standard education. Researchers measured q…

This study tested a program called PRISM, which teaches skills like stress management and goal setting, to see if it helps racial minority patients with serious illnesses feel more resilient and communicate better with their healthcare providers. The study enrolled 28 seriously i…

This study tested two different radiotherapy schedules for people with advanced non-small cell lung cancer. One group received the standard 6-week course, while the other had a shorter 4-week course guided by PET scans. The main goal was to see how patients felt during and after …

This study tested whether a brief mindfulness video could help reduce the stigma that lung cancer patients often feel, especially those from underserved groups. Researchers worked with a community advisory board of lung cancer patients to design the video. The trial enrolled 108 …

This study tested an 8-week supervised program of breathing exercises and light strength training for 30 people with advanced lung cancer (stage IIIB/IV) who were also getting chemotherapy. Those in the rehab group could walk farther, breathe better, and reported less coughing an…

This study tested whether a simple walking program, guided by a fitness tracker, could help cancer patients tolerate their chemoradiotherapy without missing treatments. 166 adults with brain, head and neck, lung, gastrointestinal, or cervical cancer participated. Patients were gi…

This study tested a 4-week nursing program based on self-efficacy theory for 300 lung cancer patients receiving CyberKnife radiation. The program included education, psychological support, and self-management training. Researchers measured changes in anxiety, pain, and quality of…

This pilot study tested a 10-week virtual group program called Mindful Self-Compassion for Lung Cancer (MSC-LC) in 79 adults with lung cancer who felt stigmatized. Participants were randomly assigned to the program or a waitlist that received mental health resources. The goal was…

This study tested a digital tool called Noona that lets advanced cancer patients track their symptoms from home. 190 adults with advanced lung or gastrointestinal cancer used the app to log symptoms and received prompts to report them weekly. The goal was to see if this improves …

This study tested a team-based nursing program for 200 people with advanced small cell lung cancer receiving chemotherapy plus immunotherapy. The program included close monitoring for side effects, help with medication adherence, nutrition and exercise support, and psychological …

This study tested whether an education and support program can help family caregivers of cancer patients feel more confident and less anxious. About 484 caregivers and patients took part. Researchers compared different types of support to see which worked best.

This study looked at whether adding a structured, gentle exercise program to standard nursing care could help reduce cancer-related fatigue and improve quality of life in people with advanced lung cancer receiving chemotherapy. One hundred patients were split into two groups: one…

This study tested whether a family-supported palliative care program could improve quality of life and emotional well-being in 110 people with advanced lung cancer. Participants were randomly assigned to either the family-supported program or standard nursing care for 8 weeks. Th…

This study tested whether practicing pranayama breathing exercises for 15-20 minutes a day, 5 days a week for 8 weeks, could help adults aged 60 and older feel less stressed, sleep better, and enjoy a higher quality of life. Researchers compared 74 participants who did the breath…

This study tested whether a mobile app helps cancer patients undergoing chemotherapy or radiation therapy report their symptoms more effectively. Over 200 participants used the app to track side effects for 8 weeks. The goal was to see if the app improves how patients recognize a…

This study tested a low-cost, portable exercise program for people with non-small cell lung cancer after surgery. The goal was to help them manage severe fatigue and improve their quality of life. 235 adults took part, and the program was designed to be safe and practical for nea…

This study tested a newer, potentially safer nerve block (MTP block) against the standard one (thoracic paravertebral block) for pain after chest surgery. 180 adults having lung surgery through a large chest incision were included. The goal was to see if the newer block provides …

This completed study tested whether motivational interviewing, a supportive counseling style, delivered through online video calls could increase the intention to quit smoking in people with lung cancer. Forty-two participants who smoked were randomly assigned to receive the inte…

This study tested the safety of a special radiation schedule called Quad Shot for people with stage IV non-small cell lung cancer who are also receiving chemotherapy or immunotherapy. The Quad Shot delivers radiation in just 2 days per cycle, up to 3 cycles, to make it easier to …

This study tested whether a nurse-led education session before thoracic surgery helps lung cancer patients recover better. 100 adults were split into two groups: one received structured education with a booklet, the other got standard care. Researchers measured pain, lung functio…

This completed trial tested a web-based remote monitoring platform called CONTINUUM+ CONNECT in 411 adults with metastatic breast, lung, colorectal, or prostate cancer. Patients used the platform to report symptoms and receive alerts, aiming to improve their physical health and q…

This trial explores whether a blood test measuring reticulocyte hemoglobin content (RET-He) can predict how well cancer patients with anemia will respond to intravenous iron treatment. The study involves adults with solid tumors who have functional iron deficiency. By checking RE…

This study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…

This trial is testing whether using whole-body PET/CT scans and liquid biopsies (blood tests that detect cancer DNA) can improve the follow-up care of people who have completed treatment for early-stage non-small cell lung cancer. The goal is to see if these advanced tools can fi…

This study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …

This study follows 1,200 people in China newly diagnosed with advanced non-small-cell lung cancer (stage IIIB/IV) that cannot be removed by surgery. Researchers will collect information from medical records and follow patients over time to see what treatments they receive, how lo…

This study compares two breathing techniques used during robotic bronchoscopy, a procedure to biopsy lung nodules. The goal is to see which method better prevents atelectasis (lung collapse) during the procedure. About 62 adults with suspicious lung nodules will be randomly assig…

This study looked at whether a lung rehab program done over video calls can help people recover after lung cancer surgery. 36 patients aged 55-75 who had part or all of a lung removed took part. They did exercises and tests like the 6-minute walk and breathing tests, all guided b…

This 100% remote study surveys 250 people diagnosed with non-small cell lung cancer before age 50. Participants answer questions about their environment, lifestyle, and family history, and may donate blood. The goal is to uncover factors linked to genetic changes that drive young…

This study interviews 55 patients with resectable non-small cell lung cancer and their doctors in the US, Germany, and Japan. The goal is to understand what treatment features they value most, such as effectiveness or side effects. Results may help align care with patient priorit…

This study is testing whether a CT-free electromagnetic navigation system can accurately locate small lung nodules before surgery, compared to the standard CT-guided method. The goal is to see if the new approach can mark nodules within 10 millimeters of their center, which is cr…

This study tests a new AI tool called GAPS-Agent that helps doctors plan surgeries for lung cancer. The tool is designed to assist less experienced doctors in making complex decisions. Researchers will compare AI-generated plans to those from a standard AI, and expert surgeons wi…

This study looks at how anti-tumor T-cell responses change in people with lung or head-and-neck cancer who are receiving radiochemotherapy. Researchers will collect blood and tumor samples to track immune markers. The goal is to understand whether this standard treatment can boos…

This study is for people with early-stage lung cancer whose cancer returned after taking the drug osimertinib. Researchers will analyze tumor or blood samples to find gene changes linked to the recurrence. The goal is to better understand why some cancers come back, which could h…

This study examines how children under 18 with cancer or a history of a stem cell transplant do when they need a machine called ECMO to help them breathe. Researchers looked at bleeding, infections, and survival rates in children treated at one hospital, and compared survival wit…

This study explores whether artificial intelligence can predict the stage and survival of non-small cell lung cancer by analyzing CT and PET scans. Researchers will train a deep learning model using existing medical records from 156 patients who had lung cancer surgery. The goal …

This trial tests whether presenting a cancer screening appointment as a pre-selected default option (opt-out) makes people at high risk for lung or stomach cancer more likely to accept it, compared to a standard opt-in approach. Participants complete an online questionnaire and d…

This study tests whether a biopsy technique called transbronchial cryobiopsy is safer than the standard method for diagnosing lung cancer. About 100 adults with known or suspected lung cancer will undergo the procedure under general anesthesia. Researchers will track complication…

This study looks at whether using suction during a lung biopsy (EBUS-TBNA) helps get better tissue samples from people with suspected lung cancer that has spread to lymph nodes. Researchers will compare samples taken with and without suction to see which method gives more materia…

This study develops and tests a tool designed to help lung cancer nurses talk to patients about clinical trials. The tool provides information on available trials, communication tips, and practical guidance. Researchers will test it in four UK hospitals to see if it improves nurs…

This study aims to develop and test a tool that helps lung cancer nurses talk to patients about clinical trials. Only about 8% of lung cancer patients in the UK join trials, and nurses often lack the time or confidence to discuss them. The tool will be tested in four UK hospitals…

This study investigates whether a simple blood test (liquid biopsy) can track how advanced non-small cell lung cancer changes during immunotherapy or targeted therapy. Researchers will analyze tumor DNA circulating in the blood to see if it can predict treatment response and dete…

This study looked at 30 people with early-stage non-small cell lung cancer who had surgery. Researchers collected blood from a vein near the tumor and from a regular arm vein to study tiny particles called exosomes. The goal was to see if these particles could help predict whethe…

This completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…

This completed study in Greece enrolled 200 people with stage 4 non-small cell lung cancer. Researchers used genetic testing to map each tumor's unique features and gave half the patients access to a digital platform to report side effects. The goal was to see if combining person…

This early-phase trial tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 patients with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side eff…

This study followed 39 lung cancer patients who received radiation therapy to see how it affected their breathing. Researchers measured lung volume and gas exchange capacity before and after treatment, looking for a 20% or greater drop in diffusion capacity at 3 months. The goal …

This completed study looked at 44 patients who had lung cancer surgery to understand how the arteries in the lungs can vary from person to person. Using CT scans and 3D models, researchers mapped these variations to help surgeons avoid complications during lobectomy. The goal was…

This study uses lung ultrasound to measure how the lungs change after surgery to remove part of a lung due to cancer. Researchers will check lung aeration before surgery, right after, and 24 hours later in about 32 adults. They aim to see if ultrasound findings relate to oxygen l…

This completed study enrolled 336 people with non-small cell lung cancer to collect detailed family cancer histories using a questionnaire. Researchers want to see if certain patterns of cancer in relatives, along with smoking and other risk factors, can help identify patients wh…

This study looked at whether a blood test called ISET can find circulating tumor cells in people with early-stage non-small cell lung cancer. Researchers checked blood samples from 256 patients before surgery to see if these cells were linked to cancer stage, type, and survival. …

This study tested whether a protein called GLUT1 could help doctors better classify lung neuroendocrine tumors. Researchers analyzed tumor samples from 36 patients to see if GLUT1 staining patterns matched tumor type. The goal was to find a more reliable diagnostic tool than curr…

This study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…

This completed study collected information from 101 patients and healthcare providers to design a care pathway for COPD in people also being treated for lung or head and neck cancer. The goal was to identify common burdens and barriers to COPD care in oncology clinics. The findin…

This study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.

This study looked at whether measuring procalcitonin (PCT) levels in the blood could help detect infections earlier in people with stage IV non-small cell lung cancer starting chemotherapy. Researchers enrolled 45 patients and took a PCT blood sample before their first chemo sess…

This study analyzed health records from over 229,000 people with newly diagnosed lung cancer in Korea to see if getting a brain MRI every year helps find cancer that has spread to the brain. The goal was to learn whether these scans catch brain metastases earlier, when they might…

This study explored sleep disorders in 37 adults with non-small cell lung cancer. Participants filled out questionnaires about their sleep, symptoms, mood, and quality of life. The goal was to create a guide to help doctors diagnose and treat sleep issues in this group, ultimatel…

This study enrolled 200 adults with lung adenocarcinoma that has spread to the bones. Researchers took bone biopsies, scans, and blood tests to measure bone and metabolic markers. The goal is to see if these markers are linked to how long patients live. This is an observational s…

This study looked at whether offering smoking cessation support to people undergoing tests for lung cancer helps them try to quit. 86 patients from several hospitals took part. Some hospitals offered extra support, while others continued their usual care. The researchers measured…

This study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…

This study reviewed the medical records of 569 adults who had surgery for lung or esophageal cancer. Researchers wanted to see if taking statins (cholesterol-lowering drugs) around the time of surgery was linked to fewer complications and better long-term outcomes. The goal is to…

This study looked at how physically active lung cancer patients are during radiation therapy. Twenty adults with lung cancer carried smartphones that counted their steps. Researchers compared step counts from the first week of treatment to the fifth week to see if activity change…

This study tested whether a special 4D PET-CT scan can help doctors better target radiation for lung cancer. Seven patients with non-small cell lung cancer received both a standard CT scan and a 4D PET-CT scan before radiotherapy. Researchers compared the tumor volumes identified…

This study tested a new way for doctors to discuss CPR with older, seriously ill patients and their families. Instead of the usual conversation, doctors followed a step-by-step guide that focused on the patient's values and explained why CPR might not help. The goal was to see if…

This study looked at 302 patients with advanced non-small cell lung cancer in Greece who were treated with a combination of nivolumab, ipilimumab, and chemotherapy as their first therapy. Researchers tracked patient characteristics, treatment patterns, and survival rates over tim…

This study looked at 24 people with lung or esophageal cancer who received radiation or chemo-radiation near the heart. Participants wore a small heart monitor to catch any heart changes that might otherwise go unnoticed. The goal was to see how often heart problems occur after s…

This completed study looked at ways to increase diversity in cancer clinical trials, focusing on breast, liver, and prostate cancers. Researchers worked with communities, doctors, and scientists in New York City to find better ways to include people of color and underserved group…

This completed study looked at 150 people with advanced non-small cell lung cancer to see if proteins and metabolites in blood and urine could help monitor how well immunotherapy is working. Researchers used mass spectrometry to measure these markers before, during, and after tre…

This study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…

This study looked at how to best set a breathing machine during lung surgery when only one lung is being used. The goal was to see if using smaller breaths with higher pressure could keep oxygen levels stable. 88 adults having lung surgery took part. The study measured oxygen in …

This study analyzed blood samples from 50 adults with advanced ALK-positive lung cancer whose disease had stopped responding to one or two ALK inhibitors. The goal was to identify genetic changes in the cancer that cause drug resistance. By matching these changes to the right nex…

This study looked at whether a lung specialist (pulmonologist) can quickly check biopsy samples during a lung cancer procedure, a job usually done by a pathologist. Researchers compared the pulmonologist's on-the-spot assessment with the pathologist's final report in 189 patients…

This study tested a smartphone app that reminds people to walk several times a day. It was designed to help lung cancer patients stay active during radiotherapy. Thirty healthy volunteers downloaded the app and rated how easy it was to use. The goal was to see if the app is user-…

This study tested a virtual navigation system that helps doctors guide a bronchoscope to lung nodules for sampling. Researchers compared results from 110 patients who used the system to historical data from standard procedures. The goal was to see if the system improves biopsy su…

This study tested whether implanting tiny gold markers near spinal tumors helps deliver radiation more accurately. Researchers also checked if giving slightly more radiation to the nearby esophagus is safe, which might improve tumor control. The study involved 41 adults with vari…

This study looked at how a gene called CYP2D6 influences pain relief from the drug oxycodone in 100 older adults (age 60+) having lung cancer surgery. Researchers measured pain and sedation levels to see if genetic differences affect how well the drug works and how safe it is. Th…

This study compared two ways for surgeons to see the borders between lung segments during surgery for early-stage non-small cell lung cancer. One method uses a green dye and a special camera, the other uses a modified inflation-deflation technique. The trial involved 272 patients…

This study tested a new cone-beam CT scanner that takes clearer pictures during radiation therapy for lung, liver, and breast cancers. 31 people participated to see if the new scanner reduces image blurring and improves accuracy. The goal is to help doctors target tumors more pre…

This study tested a new way to help surgeons remove small lung nodules during a type of keyhole surgery called VATS. Doctors used a cone-beam CT scanner to place tiny metal markers (microcoils) near the nodules before removal. The goal was to see if this method is accurate and re…

This completed study looked at how often joint pain occurs in 71 people with ovarian, colorectal, or lung cancer who were taking the drug bevacizumab. Participants filled out a questionnaire about their joint pain over 6 months. The goal was to better understand this side effect.

This phase 2 trial studied 50 people with non-small cell lung cancer to see if differences within a tumor (called heterogeneity) affect how well treatments work. Patients received one of four drugs based on their tumor's genetic changes: atezolizumab (immunotherapy), vemurafenib,…

This study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…

This study looked at the nutrition and body composition of 25 adults with non-small-cell lung cancer who were taking the drug osimertinib. Researchers measured weight, muscle mass, and strength to see how common malnutrition and muscle loss were, and how these affected quality of…

This study looked at 4000 people with advanced lung cancer who had a specific gene mutation (EGFR) and were taking a targeted pill. The goal was to find the best time to add focused radiation to shrink any remaining tumors. Researchers tracked when tumors shrank the most and wher…

This study looked at 77 never-smokers newly diagnosed with lung cancer to see how many also have sleep apnea and whether sleep apnea affects their cancer outlook. Participants had a sleep test before starting cancer treatment. The goal is to understand if sleep apnea is a hidden …

This study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…

This study looked at 135 people with advanced lung cancer, lymphoma, or other tumors treated with immunotherapy drugs called checkpoint inhibitors. Researchers collected blood and tumor samples over time to measure immune cells and molecules that might predict whether the treatme…

This study looked at chemical fingerprints (metabolites) in blood, lung tissue, and exhaled breath from 74 people with either non-small cell lung cancer or harmless lung nodules. The goal was to find differences that could help diagnose lung cancer without invasive procedures. Re…

This study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…

This study looked back at medical records of 240 adults in Poland who received a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy as their first treatment for advanced non-small cell lung cancer. The goal was to see how well the treatment worked…

This completed study looked at 1200 patients who had a CT-guided needle biopsy of a lung nodule at St. Olavs Hospital between 2012 and 2023. The goal was to track how often complications like a collapsed lung (pneumothorax), lung bleeding, or air embolism happen. By analyzing the…

This study looked at 182 older adults with blood cancer or lung cancer to see if a special calculator could predict who would have severe side effects from chemotherapy. Researchers measured patients' fitness before and after treatment to better understand how well they could han…

This study analyzed blood, urine, and tissue samples from 273 adults with brain or lung cancer who were receiving radiation therapy. The goal was to find biological markers that could predict which patients are more likely to develop serious side effects from radiation, such as l…

This pilot study looked at whether cancer patients with head and neck, lung, or digestive system cancers could wear a fitness tracker during radiation therapy. The goal was to see if tracking activity levels and quality of life is practical and might relate to treatment outcomes.…

This completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…

This study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…

This small study tested a device that paces the diaphragm in brain dead organ donors whose lungs were too damaged for transplant. The goal was to see if this approach could improve lung function enough to make the lungs usable. Only 3 people took part, so the results are very ear…

This study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…

This study tested whether free, open-source software can create 3D models of the lungs to help surgeons during lung cancer surgery. 13 patients scheduled for lung surgery had their CT scans turned into 3D reconstructions. The goal was to see if these models were easy for surgeons…

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving their first immunotherapy treatment could successfully collect small blood samples at home using a finger-prick method. The goal was to see if this approach is practical and rel…

This completed study from City of Hope Medical Center looked at 109 people to understand how genetics and social factors like income and education may affect lung cancer risk. Participants gave blood samples, had low-dose CT scans, and filled out surveys. The goal is to find clue…

This study looked at whether a simple blood test (liquid biopsy) can detect a specific resistance mutation called T790M in patients with advanced non-small cell lung cancer whose tumors stopped responding to initial targeted therapy. Researchers followed 70 patients in Tunisia, c…

This study looked at 385 adults diagnosed with their first lung or head & neck cancer to see how many continued using tobacco or alcohol over the next year. Researchers tracked smoking and drinking habits, as well as how long patients lived without the cancer getting worse. The g…

This study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …

This study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…

This study examined pieces of the Met receptor protein in tumor and healthy tissue from 56 people with non-small cell lung cancer. Researchers used blood and tissue samples taken during surgery or biopsy to see which Met fragments are present and whether they are active. The goal…

This study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…

This study created a detailed database of 518 adults with non-small cell lung cancer in the Nord Pas de Calais region of France. Researchers collected clinical information and genetic mutation data to see how factors like age, smoking, and cancer stage relate to specific mutation…

This study tested whether helping people with social needs like housing, food, or transportation could increase lung cancer screening rates. 101 adults aged 50-80 who smoked heavily were split into two groups: one got standard education about lung screening, and the other also go…

This study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…

This study looked at how doctors currently treat patients with a type of advanced lung cancer that is not causing symptoms and cannot be cured. It followed 46 patients who either received radiation therapy right away or waited until symptoms appeared. The goal was to understand t…

This study tested a program to help more people at high risk for lung cancer get a low-dose CT scan, which can catch the disease early and save lives. The program included notifying doctors, educating patients, offering financial help, and reminding patients to talk about screeni…

This completed phase 1 study in 28 healthy adults examines how the experimental cancer drug calderasib (MK-1084) changes the way the body processes two common drugs: midazolam and digoxin. Researchers measure drug levels in the blood after giving these drugs with and without cald…

This study tested whether an AI-assisted software (iCurveE) helps doctors outline organs at risk on CT scans for radiation therapy more accurately and quickly. 500 adults with lung, breast, or esophageal cancer participated. Researchers compared manual outlining, AI-only, and AI-…

This study looked at 3000 cancer patients to see which treatments work best for preventing dangerously low white blood cell counts after chemotherapy. It compared different approaches to see how well they prevent infections and improve quality of life. The goal is to give doctors…

This study tested a Turkish version of the Respiratory Distress Observation Scale (RDOS) in 100 adult palliative care patients who cannot describe their breathing trouble. The scale uses eight physical signs like heart rate and restlessness to rate distress. The goal was to see i…

This study looked at nearly 2,000 adults with lung cancer who caught COVID-19. Researchers tracked their health and checked for antibodies (immune system markers) right after infection and again 6 months after vaccination. The goal was to understand how lung cancer affects the bo…

This study aimed to find immune-related biomarkers that could predict how well patients with non-small cell lung cancer respond to the drug atezolizumab. Researchers analyzed blood and tumor samples from 100 participants to track immune cell changes and genetic markers. The goal …

This study looked at sexual problems in 553 adults with lung cancer. Researchers wanted to find out how common these issues are and how severe they can be. The goal is to help doctors better support patients during and after cancer treatment.

This study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants …

This study looked at whether using a CPAP machine (commonly used for sleep apnea) during radiation therapy can reduce the amount of radiation reaching the lungs. Eight people with left-sided breast cancer or lung cancer took part. Researchers compared lung radiation doses with an…

This completed study looked at nearly 5,000 people with non-small cell lung cancer to see if information from electronic health records could produce the same results as a famous clinical trial called FLAURA. Researchers compared patients who started taking osimertinib to those o…

This study looked at whether the time of day affects the number of cancer cells in the blood of people with advanced lung cancer. Researchers took blood samples from 27 patients at 4 a.m. and 10 a.m. before starting treatment. The goal was to see if circadian rhythms influence ho…